Get 40% Off
⚠ Earnings Alert! Which stocks are poised to surge?
See the stocks on our ProPicks radar. These strategies gained 19.7% year-to-date.
Unlock full list

S&P 500 in Ugly Close as First U.S. Omicron Case Rattles Markets

Published 12/02/2021, 05:24 AM
Updated 12/02/2021, 05:24 AM
©  Reuters

By Yasin Ebrahim

Investing.com – The S&P 500 closed lower Wednesday, after cutting its intraday gains as the U.S. confirmed its first case of the new Omicron Covid-19 strain, triggering a fresh wave of uncertainty across on Wall Street.  

The S&P 500 fell 1.2%, and had been more than 1% higher intraday. The Dow Jones Industrial Average fell 1.3%, or 462 points, and the Nasdaq slipped 1.8%.

U.S. health officials confirmed Wednesday that the first case of the Omicron variant of Covid-19 was identified in California. 

The individual – who returned from South Africa on Nov. 22 and tested positive on Nov. 29 – was “fully vaccinated and experienced mild symptoms, which are improving at this point,” said Dr. Anthony Fauci, President Joe Biden's chief medical adviser.

The news triggered a bout of uncertainty, with the CBOE Volatility Index, or so-called fear index, surging 16%, triggering a wave of selling in the broader market and overshadowed better-than-expected labor market data.      

Private payrolls grew by 534,000 in November, less than the 570,000 in October, but ahead of expectations for 525,000.

The better-than-expected jobs data comes just days ahead of the monthly nonfarm payrolls due Friday, and strengthened expectations for the Federal Reserve to step up the pace of bond tapering.

In his second day of testimony on Capitol Hill, Fed Chair Jerome Powell continued to reiterate that speeding up the taper of bond purchases would be on the agenda at the December meeting, but added that there was no reason for faster taper to be disruptive to markets.

In sign of skittish investor sentiment, utilities, a typically defensive corner of the market, was the only sector to close in the green.

AES Corporation (NYSE:AES), Alliant Energy (NASDAQ:LNT), WEC Energy (NYSE:WEC) were among the biggest gainers.

Health care stocks were pushed higher by a more than 9% surge in Vertex Pharmaceuticals (NASDAQ:VRTX) after the pharmaceutical company reported a positive update from its mid-stage focal glomerular sclerosis study.

Moderna (NASDAQ:MRNA), meanwhile, slumped more than 11% after losing an appeal against a court ruling on patents – used in the making of its Covid-19 vaccine – held by Arbutus Biopharma (NASDAQ:ABUS). Arbutus surged 44%, but was well off its session highs. 

In energy, Exxon Mobil (NYSE:XOM) was in focus after the oil major forecast a doubling of earnings and cash flow by 2027 amid plans to lower capital expenditure.

In tech, Apple (NASDAQ:AAPL) erased its intraday gains as the broader market reversed. The tech giant was up more than 1% intraday as some on Wall Street highlighted improving signs of improving supply chain pressures that could help the tech maker roll out its latest line of iPhones.

Citing signs of improved wait times for iPhones, UBS forecasts Apple to sell 80 million iPhones in the December quarter, compared with 82 million last year.

Twitter (NYSE:TWTR), meanwhile, fell more than 2% even as Cathie Wood revealed that ARK purchased 1.1 million shares of the social media company on Tuesday, amid optimism about the future of the company under the leadership of new Chief Executive Parag Agrawal.

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.